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Dysregulation of TAp63 mRNA and Protein Levels
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Karin Nylander1
Psoriasis is a chronic and excessive inflammation of the skin and is currently incurable. The cause of psoriasis
remains poorly understood and a central and cooperative role for keratinocytes and T-cells in triggering the
disease is highlighted. The p63 gene encodes six different proteins with homology to the tumor suppressor protein
p53 that are crucial for normal development of ectodermally derived structures such as skin and oral mucosa. In
this study, we have analyzed levels of the different p63 isoforms using quantitative reverse transcription-
polymerase chain reaction (RT-PCR) and immunohistochemistry in 15 patients diagnosed with psoriasis.
Quantitative RT-PCR results showed downregulation of the full-length TAp63 in psoriatic lesions compared to
both clinically normal skin from patients (Po0.001) and matched healthy controls (Po0.001); however, p63 protein
levels detected by immunohistochemistry were similar. All psoriasis lesions also had detectable levels of activated
Stat3, a protein indicated in development of the disease, whereas control tissue lacked this protein. The present
data show a different regulation of TAp63 in psoriasis, where the discrepancy between mRNA levels and protein
expression indicates a post-transcriptional regulation analogous to that seen in p53.
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INTRODUCTION
Approximately 2–3% of the population worldwide suffers
from psoriasis, a currently incurable disease with chronic and
excessive inflammation of skin and joints (Nickoloff and
Nestle, 2004). The clinical and histological features of the
disease are well described, whereas the cause of psoriasis
remains poorly understood. Originally, it was thought that the
primary cause was abnormalities in keratinocyte (KC)
biology, but now attention has focused on the activated T
lymphocytes and dendritic cells, and psoriasis is considered
to be a model Type 1 T-cell immune disorder (Gottlieb,
2005). Recently, using a novel transgenic mouse model, it
was shown that activation of a member of the Stat (signal
transducers and activators of transcription) family, Stat3, in
KC, together with activation of T-cells, leads to the induction
of psoriatic lesions (Sano et al., 2005).
The p63 gene encodes six different proteins with
homology to the tumor suppressor protein p53. The presence
of two promoters and differential splicing in the C-terminal
explains the existence of six different isoforms: TAp63a,
TAp63b, TAp63g, DNp63a, DNp63b, and DNp63g (Yang
et al., 1998). Similarly to p53, the p63 proteins can act as
transcription factors, activating or repressing expression from
a variety of gene promoters (Yang et al., 1998; Shimada et al.,
1999). p63 is believed to have an essential role in the
development and differentiation of the epidermis. p63
knockout mice lacking all p63 proteins lack normal
epidermal structures such as skin, hair follicles, oral mucosa,
teeth, salivary glands, etc (Yang et al., 1998). It has also been
shown that during embryogenesis, TAp63 may be the
molecular switch required for initiation of epithelial stratifi-
cation. TAp63a expression further inhibits terminal differ-
entiation, an inhibitory effect that is counterbalanced by
DNp63a expression (Koster et al., 2004).
In the mature epidermis, DNp63a is the main isoform and
is expressed predominantly in the basal layers whereas its
expression is downregulated in more differentiated layers
(Yang et al., 1998; Nylander et al., 2000, 2002; Thurfjell
et al., 2004). It has been proposed that DNp63a expression
maintains the proliferative potential of basal cells and must
be downregulated for terminal differentiation to take place
(Koster and Roop, 2004). Expression of the full-length TAp63
mRNA is also seen (Bamberger et al., 2002, 2005; Thurfjell
et al., 2004), and TAp63 proteins are found through the
whole epithelial thickness (Nylander et al., 2002). This
indicates a different role for TAp63 proteins in the mature
epithelium compared to the developing epithelium; these
proteins in the latter are responsible for initiation of
stratification, but may have a more differentiation-related
responsibility in the mature epithelium. Several experiments
using transient expression of different TAp63 variants have
also provided an insight into their role in differentiated
& 2006 The Society for Investigative Dermatology www.jidonline.org 137
ORIGINAL ARTICLE
Received 1 July 2005; revised 17 August 2005; accepted 13 September 2005
1Department of Medical Biosciences/Pathology, Umea˚ University, Umea˚,
Sweden; 2Department of Dermatology and Venereology, University Hospital,
Umea˚, Sweden and 3Department of Molecular and Cellular Pathology,
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
Correspondence: Dr Xiaolian Gu, Department of Medical Biosciences/
Pathology, Umea˚ University, Bldg 6M, 2nd floor, SE – 901 85 Umea˚,
Sweden. E-mail: xiaolian.gu@medbio.umu.se
Abbreviations: KC, keratinocyte; RT-PCR, reverse transcription-polymerase
chain reaction
epithelial formation (Westfall and Pietenpol, 2004). How-
ever, the exact function of the individual proteins in this
process is not clear.
Recently, Shen et al. (2005) examined the expression of p63
in various stages of plaque-type psoriasis by immunohistochem-
istry using a monoclonal anti-p63 antibody that recognizes all
p63 isoforms and suggested that p63 is involved in epidermal
remodeling in psoriasis. Decreased levels of p63 mRNA have
also been seen in different subpopulations of psoriatic
compared to normal epidermis (Franssen et al., 2005). Here,
in order to provide further insight into p63 functions in psoriatic
epidermis, we investigated the expression and levels of p63
isoforms by both quantitative reverse transcription-polymerase
chain reaction (RT-PCR) and immunohistochemistry. The results
showed a downregulation of TAp63 mRNA in human psoriatic
lesions whereas protein levels were the same. This discrepancy
between mRNA levels and protein expression indicates that
TAp63 is differentially regulated in psoriasis, suggesting a role
for p63 in the development or maintenance of this common
disease.
RESULTS
Reduced p63 mRNA levels in psoriatic lesions
In quantitative RT-PCR analysis, five primer sets specifically
amplifying the two N-terminal variants (DNp63 and TAp63)
and the three C-terminal variants (p63a, p63b, and p63g)
were used. Results showed that p63a and DNp63 isoforms
had the highest mRNA levels of all p63 isoforms, and a slight
reduction in DNp63 mRNA levels was found in psoriatic
lesions compared to patients’ own clinically normal epider-
mis with a fold change of 1.2 (Po0.05) (Figure 1a). mRNA
levels for TAp63 were significantly lower in lesions than in
clinically normal epidermis (5.2-fold; Po0.001) and the
matched controls (7.7-fold; Po0.001). p63g mRNA levels
were also significantly lower in lesions than in clinically
normal epidermis (2.2-fold; Po0.01) and the matched
healthy controls (2.0-fold; Po0.01) (Figure 1b).
Similar p63 protein expression pattern
Expression of different p63 isoforms was also studied by
immunohistochemistry using polyclonal antibodies specifi-
cally recognizing TAp63, DNp63, and p63a (Figure 2).
Proteins were detected in the nuclei of epithelial cells in all
samples. In accordance with previous results (Nylander et al.,
2002), DNp63 proteins were expressed in basal and para-
basal cell layers through half to two-thirds of the epithelial
thickness. TAp63 staining was weaker than that of DNp63,
and these proteins were located through the whole epithe-
lium. Staining of p63a proteins showed distribution of these
through the whole epithelium. Immunostaining of psoriatic
lesions and clinically normal epidermis from the same patient
showed the same signal intensity and the same protein
expression pattern.
Detection of activated Stat3 and no difference in expression
of p53 in psoriatic lesions
Positive staining for nuclear Phospho-Stat3, an activated
form of Stat3, was seen in all psoriatic lesions, whereas
Phospho-Stat3 was not detected in normal noninvolved
epidermis from patients or in epidermis from matched
controls (Figure 3). No difference in expression of p53 was
seen between psoriasis lesions and normal noninvolved
epidermis or matched controls (data not shown).
DISCUSSION
Deregulated p63 and epidermis remodeling
In the present study, we show a downregulation of p63
mRNA in psoriatic lesions as assessed by quantitative RT-
PCR. TAp63 isoforms were significantly downregulated in
lesions compared to clinically normal skin in the same
patients (Po0.001) as well as compared to clinically normal
skin in healthy sex- and age-matched controls (Po0.001).
However, when using immunohistochemistry and an anti-
body recognizing all three TA isoforms, no obvious reduction
in TAp63 protein expression was seen in psoriatic lesions. A
discrepancy between p63 protein expression and mRNA
levels has previously been reported, showing accumulation
of TAp63a and TAp63g, respectively, after DNA-damaging
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Figure 1. Relative expression of different p63 isoforms in matched control
(C), clinically normal epithelium from psoriasis patient (N) and psoriasis
lesion (L) assessed by quantitative RT-PCR. (a) Relative mRNA levels for p63a
and DNp63 isoforms. (b) Relative mRNA levels for TAp63, p63g, and p63b
isoforms. Each reaction was run in duplicate, and a mean value of the two
samples was calculated. Data are mean7SEM, n¼ 15. *Po0.05, **Po0.01,
***Po0.001 by the Wilcoxon signed rank test compared to the clinically normal
epithelium, or by the Mann–Whitney U-test compared to matched controls.
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treatment (eg UVC or actinomycin D) without accompanying
increase in the levels of mRNA (Katoh et al., 2000; Okada
et al., 2002).
The stability of the p63 proteins is regulated by a
mechanism similar to the p53–MDM2 feedback loop that
involves proteosomal-mediated degradation, although MDM-
2 itself is not involved in p63 stability (Okada et al., 2002;
Ying et al., 2005). Like p53, the stability of p63 is intimately
linked to transcriptional activity (Ying et al., 2005). The TA
domains of p63 and p53 are crucial in the proteosomal
degradation pathway, a site lacking in the DNp63 isoforms.
Again, analogous to p53, TAp63 is phosphorylated following
certain stimuli, and phosphorylation stabilizes the protein,
although the sites and kinases involved are not known for p63
(Okada et al., 2002). Thus, post-translational modification of
the TA domain of p63 inhibits degradation and, in
accordance with p53, causes stabilization, accumulation,
and activation of the protein. The present data showing a
clear difference in regulation of p63 proteins in psoriasis with
maintained expression despite decreased mRNA levels
indicate a differential and most likely post-translational
modification of the proteins. In view of the known roles of
p63 in KC differentiation and development, this deregulation
of TAp63 is likely to play a role in the development or
maintenance of psoriasis.
The transcriptional targets of TAp63 isoforms include
p21WAF1/Cip1 (Osada et al., 1998) and Jagged-1 (Sasaki et al.,
2002), genes required for terminal differentiation of KC
(Koster and Roop, 2004). TAp63 also seems to be involved in
epidermal differentiation through regulation of the epidermal
growth factor receptor (Nishi et al., 2001), loricrin, and
involucrin (De Laurenzi et al., 2000). Even if the exact
mechanism of how altered TAp63 affects KC differentiation is
far from understood, the present data are of great interest and
importance for trying to understand psoriasis, a disease that is
characterized by KC hyperproliferation and altered differ-
entiation.
Statistically, there was no significant difference between
psoriatic lesions and matched controls concerning mRNA
levels of DNp63. However, compared to clinically normal
skin of the same patient, DNp63 mRNA was significantly
reduced in psoriatic lesions (1.2-fold; Po0.05), whereas no
obvious difference was seen in protein expression when using
immunohistochemistry. Even with a strict correlation be-
tween levels of mRNA and amount of protein produced, this
minor change, even if statistically significant, in mRNA
levels, makes it hard to detect changes in protein expression
using a nonquantitative method. Concerning stability of the
DNp63 proteins, sumo conjugation has been reported to be of
interest, at least for the DNp63a isoforms (Ghioni et al.,
2005).
Activated Stat3 and exaggerated immune response
Recently, activated Stat3 was found in human psoriatic
lesions and, together with activated T-cells, was found to be
required for development of psoriasis in a mouse model (Sano
et al., 2005). Stat3 is a member of the Stat family and Stats are
latent cytoplasmic signal-dependent transcription factors
involved in transmitting extracellular signals to the nucleus
and also involved in various biological activities, including
cell growth, survival, angiogenesis, migration, and immune
evasion (Yu and Jove, 2004). The activation of Stat3 during
the development and maintenance of psoriasis is most
likely due to growth factors and cytokines produced during
wound healing or secreted by activated T-cells and other
Figure 2. Distribution of p63 in clinically normal epithelium and lesion from
patient with psoriasis. The formalin-fixed biopsies were paraffin embedded
and stained for TAp63, DNp63, and p63a isoforms. Proteins were detected in
the nuclei of normal skin as well as psoriasis lesions. Clinically normal
epidermis and psoriatic lesions showed the same signal intensity and the same
protein expression pattern. TAp63 staining was seen through the whole
epithelium in clinically normal epidermis (a) and psoriatic lesion (b). DNp63
proteins were expressed in basal and parabasal cell layers and through half to
two-thirds of the epithelial thickness in clinically normal epidermis (c) and
psoriatic lesion (d). p63a proteins were seen through the whole epithelium in
clinically normal epidermis (e) and psoriatic lesion (f). Scale bar: 50 mm.
Figure 3. Expression of activated Stat3 in clinically normal epithelium and
lesion from patient with psoriasis. Formalin-fixed biopsies were paraffin
embedded and stained for activated Stat3. (a) No activated Stat3 was seen in
clinically normal epidermis from a psoriasis patient. (b) Cells expressing
activated Stat3 are present in psoriatic lesion. Scale bar: 50 mm.
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inflammatory cells (Sano et al., 2005). In our material, we
also detected activated Stat3 in psoriatic lesions, whereas no
activated Stat3 was detected in clinically normal skin from
psoriasis patients. The latter is in contrast to Sano et al.
(2005), who reported the presence of activated Stat3 also in
uninvolved skin of psoriasis patients. This difference in results
could be explained by their use of ‘‘adjacent uninvolved
epidermis in psoriatic patients’’, whereas we used clinically
normal skin separated from the psoriatic lesion by several
centimeters. The negative results in our samples show that
clinically normal epidermis at a distance from the psoriatic
lesion has normal Stat3 signaling. As wild-type p53 reduces
phosphorylation of Stat3 (Lin et al., 2002), and TAp63 in
many cases is as efficient as p53 in activation and
suppression (Ghioni et al., 2002), the presence of activated
Stat3 accompanied by unchanged levels of p53 protein and
downregulated levels of TAp63 mRNA in psoriasis lesions
could indicate a role also for activated TAp63 in the control
of Stat3 activation.
It has been suggested that the existing abnormalities in the
signaling apparatus of psoriasis KC cause them to act in an
exaggerated wound-healing response when they are sub-
jected to stress from internal or external agents (McKenzie
and Sabin, 2003). Mild skin trauma can trigger psoriasis,
possibly by release of preformed or rapidly produced
cytokines by KC, such as IL-1 and tumor necrosis factor
(Nylander Lundqvist et al., 1997; Nickoloff and Nestle,
2004). Therefore, the existing abnormalities in psoriatic KC,
for example, deregulated TAp63 and Stat3 signaling, might
allow KC to act in an exaggerated response to external agents
such as physical trauma. Studies of the interaction of Stat3
and p63 in human epithelial KC will help to understand the
pathological process in psoriasis.
In summary, psoriasis is a complex disease with abnorm-
alities in both KC biology and immune system. Numerous
growth-, differentiation-, and immune response-related fac-
tors are involved, and several signaling pathways have been
suggested. Data from the present study show a differential
regulation of TAp63 in psoriasis, which could indicate a role
for these isoforms in the development of psoriasis. Additional
studies are, however, needed in order to elucidate the
regulation of p63 isoforms in psoriasis as well as their role in
KC terminal differentiation.
MATERIALS AND METHODS
Material
After informed consent, 15 patients diagnosed with psoriasis
volunteered to participate in the study, eight women and seven
men, with a mean age of 46 years (range 23–73 years). All patients had
had their diagnosis for several years, and the diagnosis had been
clinically confirmed by a dermatologist with or without accompany-
ing histological verification. Patients were present or former patients at
the Dermatological Clinic receiving different kinds of treatment, such
as potent topical steroids and UVB. As controls, healthy age- and sex-
matched volunteers were used. None of these volunteers had any
former history of psoriasis or other dermatosis. The study was
approved by the Ethics Committee at Umea˚ University (Um dnr 04-
035 M) and performed in accordance with the Declaration of Helsinki.
Two punch biopsies with a diameter of 4 mm were taken. A total
of 11 of the psoriasis patients had lesions on their buttocks, and
biopsies were taken at that site. Of the remaining four patients, three
had lesions on their arms and one on the back, and biopsies were
therefore taken at those sites. Biopsies from clinically normal skin
from all psoriasis patients and matched controls were taken from the
buttocks. One biopsy from each site was snap-frozen in liquid
nitrogen for RNA extraction. The other biopsy was divided into two,
and one half fixed in neutral buffered formalin for immunohisto-
chemical analysis and the other half snap-frozen in liquid nitrogen.
RNA extraction and cDNA synthesis
RNA was extracted using an RNaeasy mini kit (Qiagen, GmbH,
Hilden, Germany) and stored at 801C until use. cDNA was
synthesized using a ‘‘1st strand synthesis kit for RT-PCR (AMV)’’
(Roche Diagnostics, Mannheim, Germany) according to the manu-
facturer’s instructions and 0.5 mg total RNA was added into a total
reaction volume of 20 ml.
Quantitative RT-PCR
Quantitative RT-PCR for p63 expression was performed with a
human p63/b-actin multi-parametric kit (Search LC, Heidelberg,
Germany) and analyzed on a Lightcyclert from Roche. In brief,
cDNA was diluted 12 times and then mixed with the different primer
sets to amplify each of the p63 splice variant mRNAs individually
and, simultaneously, to amplify b-actin to serve as an internal
control for cDNA integrity and relative cDNA quantity in the
different tissue samples. Primers were selected to bridge intronic
sequences in order to discriminate between amplification of cDNA
and contaminating genomic DNA. For amplification of p63g
isoforms, intron bridging was not possible. In order to check for
DNA contamination, amplification of total RNA before cDNA
synthesis was performed in parallel with amplification of the cDNA.
Reactions were analyzed on the Lightcyclert with one denaturation
cycle, 35 amplification cycles, one melting curve analysis cycle,
and, finally, one cooling cycle. Reactions were run in duplicate, and
a mean value of the two samples was calculated. A difference of at
most 25% between the samples was accepted. Results were
expressed as the relative amount of product adjusted for the level
of internal control amplification obtained for that sample (Thurfjell
et al., 2004).
Immunohistochemical staining
The formalin-fixed biopsies were paraffin embedded and analyzed
using immunohistochemistry. Three polyclonal p63 antibodies that
specifically recognize TAp63, DNp63, and p63a isoforms (KN-TA,
KN-D, and KN-a) were used (Nylander et al., 2002). As activation of
Stat3 has been implicated in the development of psoriasis (Sano
et al., 2005), and as wild-type p53 reduces phosphorylation of Stat3
and thus its activity (Lin et al., 2002), we also stained slides for Stat3
and p53. Monoclonal antibodies against phosphorylated Stat3
(Phospho-Stat3; Cell Signaling Technology Inc., Beverly, MA) and
p53 (DO7; Novocastra, Immunkemi F&D, Ja¨rfa¨llo, Sweden) were
used in the staining procedure on consecutive sections. Antibodies
were used at the following concentrations: KN-TA 1:750; KN-D
1:2000; KN-a 1:450; Phospho-Stat3 1:20; and DO7 1:25. Sections
were dewaxed, rehydrated by standard procedures, and subjected to
boiling in 10 mM citrate buffer (pH 6.0) for 15 minutes using a
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microwave oven for antigen retrieval. Staining was performed using
a Ventana staining machine (Ventana Medical Systems Inc., Tucon,
AZ) and reagents according to the supplier’s recommendation.
Statistical analysis
For pairwise analysis of the psoriatic lesion and corresponding
clinically normal skin from the same patient, the Wilcoxon signed
rank test was used, and for comparison of patients to control, the
Mann–Whitney U-test was applied.
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